Anat Cohen-dayag on licensing
From A Biopharma Pivot Story With Compugen's Dr. Anat Cohen-Dayag · · Life Science Connect
“We entered into a collaboration with Bayer where we were licensed to them the rights to develop drugs for one of the targets that we identified.”
On , Anat Cohen-dayag, Executive Chair at Compugen, spoke about licensing during A Biopharma Pivot Story With Compugen's Dr. Anat Cohen-Dayag on Life Science Connect.
About Anat Cohen-dayag
Dr. Anat Cohen-Dayag, Executive Chair at Compugen, discussed the company's transformation from a computational biology service provider into a clinical-stage biopharmaceutical company focused on cancer immunotherapy. In a 2021 interview, she described how the company leveraged its status as a public company, using different financial instruments to fund its pipeline before having sufficient early-stage data to pursue public offerings. She noted that Compugen entered into a collaboration with Bayer, licensing to them the rights to develop drugs for one of the targets the company identified. Cohen-Dayag also outlined Compugen's strategy, which includes advancing its clinical-stage pipeline, developing early-stage programs to feed that pipeline, and using its computational engine to sustain its own discoveries. She stated that after presenting clinical data and establishing collaborations with Bristol-Myers Squibb, AstraZeneca, and Bayer, the company conducted another round of offering.